Literature DB >> 30911936

Advances, Challenges, and Perspectives in Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis.

Elena Abati1, Nereo Bresolin1,2, Giacomo Comi1,2, Stefania Corti3,4,5.   

Abstract

Finding an effective therapeutic approach is a primary goal for current and future research for amyotrophic lateral sclerosis (ALS), a fatal neurological disease characterized by degeneration and loss of upper and lower motor neurons. Transplantation approaches based on stem cells have been attempted in virtue of their potential to contrast simultaneously different ALS pathogenic aspects including either the replacement of lost cells or the protection of motor neurons from degeneration and toxic microenvironment. Here, we critically review the recent translational research aimed at the assessment of stem cell transplantation safety and feasibility in the treatment of ALS. Most of these efforts aim to exert a neuroprotective action rather than cell replacement. Critical aspects that emerge in these studies are the need for the identification of the most effective therapeutic cell source (mesenchymal stem cells, immune, or neural stem cells), the definition of the optimal injection site (cortical area, spinal cord, or muscles) with a suitable administration protocol (local or systemic injection), and the analysis of therapeutic mechanisms, which are necessary steps in order to overcome the hurdles posed by previous in vivo human studies. New perspectives will also be offered by the increasing number of induced pluripotent stem cell-based therapies that are now being tested in clinical trials. A thorough analysis of recently completed trials is the foundation for continued progress in cellular therapy for ALS and other neurodegenerative disorders.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Induced pluripotent stem cells; Mesenchymal stem cells; Motor neuron; Neural stem cells; Regulatory T cells; Stem cell transplantation

Mesh:

Year:  2019        PMID: 30911936     DOI: 10.1007/s12035-019-1554-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  10 in total

Review 1.  Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases.

Authors:  Elena Abati; Arianna Manini; Giacomo Pietro Comi; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2022-06-21       Impact factor: 9.207

2.  Dynamic extrinsic pacing of the HOX clock in human axial progenitors controls motor neuron subtype specification.

Authors:  Vincent Mouilleau; Célia Vaslin; Rémi Robert; Simona Gribaudo; Nour Nicolas; Margot Jarrige; Angélique Terray; Léa Lesueur; Mackenzie W Mathis; Gist Croft; Mathieu Daynac; Virginie Rouiller-Fabre; Hynek Wichterle; Vanessa Ribes; Cécile Martinat; Stéphane Nedelec
Journal:  Development       Date:  2021-03-29       Impact factor: 6.868

3.  ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS.

Authors:  Roberta Bonafede; Ermanna Turano; Ilaria Scambi; Alice Busato; Pietro Bontempi; Federica Virla; Lorenzo Schiaffino; Pasquina Marzola; Bruno Bonetti; Raffaella Mariotti
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

4.  Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.

Authors:  Na Song; Hiroaki Wakimoto; Filippo Rossignoli; Deepak Bhere; Rachele Ciccocioppo; Kok-Siong Chen; Jasneet Kaur Khalsa; Ilenia Mastrolia; Anna Valeria Samarelli; Massimo Dominici; Khalid Shah
Journal:  Stem Cells       Date:  2021-03-07       Impact factor: 5.845

5.  Proteomic Characterization of Human Neural Stem Cells and Their Secretome During in vitro Differentiation.

Authors:  Jakub Červenka; Jiřina Tylečková; Helena Kupcová Skalníková; Kateřina Vodičková Kepková; Ievgeniia Poliakh; Ivona Valeková; Lucie Pfeiferová; Michal Kolář; Michaela Vaškovičová; Tereza Pánková; Petr Vodička
Journal:  Front Cell Neurosci       Date:  2021-01-28       Impact factor: 5.505

Review 6.  Motor neuron replacement therapy for amyotrophic lateral sclerosis.

Authors:  Bochao Liu; Mo Li; Lingyan Zhang; Zhiguo Chen; Paul Lu
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

7.  Human ESC-derived immunity- and matrix- regulatory cells ameliorated white matter damage and vascular cognitive impairment in rats subjected to chronic cerebral hypoperfusion.

Authors:  Yilong Zhao; Jun Wu; Da Li; Jing Liu; Weiqi Chen; Zongren Hou; Kailun Liu; Lingling Jiang; Xiaowei Chen; Liu Wang; Baoyang Hu; Fangrong Zong; Yukai Wang; Yilong Wang
Journal:  Cell Prolif       Date:  2022-04-19       Impact factor: 8.755

8.  A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.

Authors:  Merit E Cudkowicz; Stacy R Lindborg; Namita A Goyal; Robert G Miller; Matthew J Burford; James D Berry; Katharine A Nicholson; Tahseen Mozaffar; Jonathan S Katz; Liberty J Jenkins; Robert H Baloh; Richard A Lewis; Nathan P Staff; Margaret A Owegi; Donald A Berry; Yael Gothelf; Yossef S Levy; Revital Aricha; Ralph Z Kern; Anthony J Windebank; Robert H Brown
Journal:  Muscle Nerve       Date:  2022-01-05       Impact factor: 3.852

Review 9.  Advancing Stem Cell Therapy for Repair of Damaged Lung Microvasculature in Amyotrophic Lateral Sclerosis.

Authors:  Svitlana Garbuzova-Davis; Robert Shell; Hilmi Mustafa; Surafuale Hailu; Alison E Willing; Paul R Sanberg; Cesario V Borlongan
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 10.  A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?

Authors:  Xiaojiao Xu; Dingding Shen; Yining Gao; Qinming Zhou; You Ni; Huanyu Meng; Hongqin Shi; Weidong Le; Shengdi Chen; Sheng Chen
Journal:  Transl Neurodegener       Date:  2021-08-10       Impact factor: 8.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.